Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, single center study, aiming to investigate safety and
efficacy of etoposide and carboplatin (administered intravenously) in combination with
anlotinib (administered orally) in treatment-naive advanced NSCLC.